Key Takeaway:
- Omvoh ulcerative colitis treatment shows promising results: Lilly’s analyses found that some patients with ulcerative colitis and Crohn’s disease achieved multiple treatment goals after one year.
- Previously treated patients also benefited: Some patients whose earlier biologic treatments failed achieved deep remission with Omvoh.
- Further research is needed: The findings come from post hoc clinical trial analyses and do not guarantee the same outcomes for all patients.
Eli Lilly says new analyses of its drug Omvoh show that patients with ulcerative colitis and Crohn’s disease can achieve multiple treatment goals simultaneously after one year, including those whose previous biologic treatments failed.
Omvoh Helps More Patients Reach Combined Treatment Goals
The analyses, announced Thursday, examine data from Lilly’s LUCENT and VIVID clinical trial programs. They evaluate mirikizumab, sold as Omvoh, against combined measures of disease control rather than individual symptoms or signs of inflammation.
In the LUCENT-2 analysis of ulcerative colitis, 27.7% of patients receiving Omvoh achieved comprehensive disease control at one year, compared with 14% receiving a placebo. The measure included symptom relief, endoscopic and tissue-level remission, normalized inflammation markers, and no corticosteroid use.
In the VIVID-1 analysis of Crohn’s disease, 20.4% of patients treated with Omvoh achieved deep remission without corticosteroids, compared with 2% in the placebo group. This measure required simultaneous clinical remission, endoscopic remission, and freedom from corticosteroid use.
The findings come from post hoc analyses of existing Phase 3 trial data, meaning researchers examined previously collected results using additional outcome measures. The analyses do not represent new regulatory approvals or establish that every patient will achieve these outcomes.
Patients With Previous Treatment Failures Also Show Progress
The results included patients who had previously experienced treatment failure with biologic medicines, a group that can be more difficult to treat. More than one-third of patients in the ulcerative colitis analysis and nearly half of those in the Crohn’s disease analysis had experienced previous biologic treatment failure.
Among patients with ulcerative colitis who experienced prior biologic treatment failure, Omvoh ulcerative colitis treatment helped 23.4% achieve comprehensive disease control, compared with 9.4% receiving a placebo. In Crohn’s disease, 15.7% of Omvoh-treated patients with prior biologic failure achieved corticosteroid-free deep remission, while none in the placebo group reached that endpoint.
Anabela Cardoso, senior vice president of Lilly Immunology Medical Affairs, said the findings reflect a broader approach to measuring treatment success.
“Treatment in inflammatory bowel disease is often measured one endpoint at a time,” Cardoso said in a company statement. She added that the results showed patients could achieve multiple treatment goals at once and were more likely to report better quality of life.
Patients who met the combined treatment goals were also more likely to report remission on the Inflammatory Bowel Disease Questionnaire, a measure of health-related quality of life.
Lilly Seeks Broader Measures of Disease Control
Inflammatory bowel disease, or IBD, includes ulcerative colitis and Crohn’s disease, chronic conditions that can cause digestive symptoms and intestinal inflammation. Treatment often aims to reduce symptoms, control inflammation, and prevent complications.
Stefan Schreiber, a physician and researcher at University Hospital Schleswig-Holstein and Christian-Albrecht University of Kiel in Germany, discussed the ulcerative colitis findings in an interview with HCPLive. He said the results were notable among patients who had not previously failed biologic treatment, with about one in three reaching the combined disease-control target.
Lilly is presenting the analyses at medical meetings, including United European Gastroenterology Week in Barcelona, Spain. The company is also studying Omvoh in combination with other medicines to assess whether these approaches can improve initial treatment responses while maintaining long-term disease control.
The findings support Lilly’s effort to position Omvoh ulcerative colitis treatment around broader treatment goals, but the analyses have limitations because they were conducted after the original trials. Further research will help determine how these combined measures translate into long-term outcomes in routine clinical care.
Visit The Lifesciences Magazine For The Most Recent Information.
